baber/WOPTO huggingface dataset:
Patent NZ-601931-A (NZ)
Title: Imidazo [1, 2 -a] pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
Inventor: VAN GOOL MICHIEL LUC MARIA
IPC: A61K31/4985
Filed: 2011-03-08
Abstract: 601931 Disclosed is are imidazo[1,2-a]pyrazine compounds of formula (I), wherein: R1 is a saturated nitrogen containing heterocycle as defined herein which is attached to the imidazo[1,2-a]pyrazine through a nitrogen atom, or else R1 is selected from the group consisting of unsubstituted pyridinyl; pyridinyl substituted with 1 or 2 substituents selected from the group consisting of halogen, alkyl, trifluoromethyl and alkyloxy; and unsubstituted tetrahydropyranyl; R2 is selected from the group consisting of hydrogen; alkyl; trifluoromethyl; cycloalkyl; alkyloxy; and cyano; R3 is selected from the group consisting of hydrogen; alkyl; cycloalkyl; and alkyl substituted with 1,2 or 3 fluoro atoms; Het is a 5- or 6- membered heterocyclic ring, selected from the group consisting of pyridinyl; pyrimidinyl; pyridazinyl; pyrazinyl; pyrrolyl; oxazolyl; thiazolyl; imidazolyl; pyrazolyl; isothiazolyl; isoxazolyl; oxadiazolyl and triazolyl; and wherein the remaining substituents are as defined within the specification. Representative compounds include 2-methyl-8-(4-morpholinyl)-3-[6-(tetrahydro-2H-pyran-4-yl)-3-pyridinyl]-imidazo[1,2-a]pyrazine, 3-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-2-methyl-8-(4-morpholinyl)imidazo[1,2-a]pyrazine, 3-[6-(2-methoxyethoxy)-3-pyridinyl]-2-methyl-8-(4-morpholinyl)-imidazo[1,2-a]pyrazine, 3-(6-cyclopropyl-3-pyridinyl)-2-methyl-8-(4-morpholinyl)-imidazo[1,2-a]pyrazine, 3-[6-(ethoxymethyl)-3-pyridinyl]-2-methyl-8-(4-morpholinyl)imidazo[1,2-a ]pyrazine and 3-[2-(2-methoxyethyl)-5-pyrimidinyl]-2-methyl-8-(4-morpholinyl)imidazo[1,2-a]pyrazine. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound as defined above and a pharmaceutically acceptable carrier or excipient, for the treatment or the prevention of neurological, psychiatric or metabolic disorders and diseases, including schizophrenia, drug induced psychosis, obsessive-compulsive disorder, generalized anxiety disorder, Huntington’s disease, dyskinesia, Parkinson’s disease, depression, bipolar disorders, dementia, Alzheimer’s disease dementia, attention deficit/hyperactivity disorder, drug abuse, pain, acute and chronic pain states, severe pain, intractable pain, neuropathic pain, post-traumatic pain, diabetes and obesity.
Patent NZ-602627-A (NZ)
Title: Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists
Inventor: DOLENTE COSIMO
IPC: A61K31/5517
Filed: 2011-04-18
Abstract: Disclosed herein are heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of general formula I, wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as V1a receptor modulators, in particular as V1a receptor antagonists and as such are useful in the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behaviour. Examples of particularly preferred compounds include: trans-8-Chloro-1-(4-pyridin-2-yl-cyclohexyl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene * 2 HCl, trans-8-Chloro-5-methyl-1-(4-pyridin-2-yl-cyclohexyl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene, trans-8-Chloro-5-methyl-1-[ 4-( 6-methyl-pyridin-2-yl)-cyclohexyl] -5 ,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene, trans-8-Chloro-5-(2,2-difluoroethyl)-1-(4-(3-fluoropyridin-2-yl)cyclohexyl)-5,6-dihydro-4H-benzo[e][1,2,4]triazolo[4,3-a][1,4]diazepine, trans-8-Chloro-5-methyl-1-(4-pyrazin-2-yl-cyclohexyl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene.
Patent NZ-603375-A (NZ)
Title: Biomarkers for the treatment of psoriasis
Inventor: SCHAFER PETER H
IPC: G01N33/50
Filed: 2011-06-15
Abstract: Discloses a method of predicting or monitoring a patients response to psoriasis treatment comprising: Measuring a sample for a level of cell marker (selected from CD3, CD56, ICAM-1, Foxp3 or HLA-DR), Langerin or mRNA (selected from Keratin 16, IL-12/IL-23 940, IL-23 p19, IL-17A, IL-22, DEFB4, MX-1, IL-10, IFN-y, CXCl9) and Comparing the level of cell marker, langerin or mRNA in the cells culture in the presence of cyclopropanecarboxylic acid { 2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl} -amide, Wherein a decreased level of the cell marker, langerin or mRNA in the sample indicates the likelihood of an effective patient response
Patent NZ-603958-A (NZ)
Title: Method of treating a musculoskeletal disorder or connective tissue disorder in a subject with prostate cancer with the GNRH antagonist Degarelix
Inventor: PERSSON BO-ERIC
IPC: A61K38/08
Filed: 2009-02-10
Abstract: 603958 Disclosed is the use of degarelix in the manufacture of a medicament for the reduction of musculoskeletal disorder and/or connective tissue disorder in a subject treated for prostate cancer.
Patent NZ-605616-A (NZ)
Title: Roof anchor method and apparatus with an anchor block inserted through a hole and positioned independently of a fixing shaft of the anchor.
Inventor: POLDMAA ARVO
IPC: F16B13/04
Filed: 2011-05-27
Abstract: A roof anchor assembly for a roof is disclosed. The roof anchor assembly includes a roof anchor and an anchor block (12). The roof anchor has a shaft for insertion through a hole (33) in the covering material (34) and support structure (35) of the roof. The anchor block (12) is capable of being inserted through the hole (33) independently of the roof anchor prior to insertion of the shaft. The anchor block (12) has means (16) to suspend it and draw it up to the underside surface of the roof support structure (35). The anchor block has a hole (15) which engages the shaft of the roof anchor when the anchor is subsequently inserted in the hole (33) to secure the roof anchor to the roof.
Patent NZ-606052-A (NZ)
Title: Apparatus for disease detection
Inventor: YU CHRIS C
IPC: G01N35/00
Filed: 2011-06-30
Abstract: Among others, the present invention provides apparatus for detecting a disease, comprising a system delivery biological subject and a probing and detecting device, wherein the probing and detecting device includes a first micro-device and a first substrate supporting the first micro-device, the first micro-device contacts a biologic material to be detected and is capable of measuring at the microscopic level an electric, magnetic, electromagnetic, thermal, optical, acoustical, biological, chemical, physical, or mechanical property of the biologic material.
Patent NZ-606358-A (NZ)
Title: Method and apparatus for leak testing containers
Inventor: LEHMANN MARTIN
IPC: G01M3/20
Filed: 2010-10-25
Abstract: Disclosed is a method for leak testing containers filled with a consumer product to test if the vessel or bottle is suitably sealed from the outside environment and the container contents maintain freshness. The method comprises the step of monitoring presence in the surrounding of the container of at least one analyte, the material composition thereof being dependent from the consumer product and exploiting a result of the monitoring as leak indicative, the monitoring comprising mass spectrometry. The method comprises inline testing up to each container of a stream of the containers and providing subsequent containers of the stream within respective test chambers moved as a test chamber stream and controllably time multiplexing an operational gas stream-connexion from the interiors of the test chambers to an input port to a single arrangement performing the mass spectrometry. Each of the test chambers is controllably connected, and moved as a test chamber stream, to a respective output line. At least two collector chambers are provided. The collector chambers are moved into gas stream communication with respective ones of the output lines and collecting in the at least two collector chambers a dose of gas from respective different ones of the output lines. An input line is provided to the mass spectrometry and sequentially moving one of the collector chambers after the other of the collector chambers with the respectively collected dose into gas stream communication with the one input line to the mass spectrometry and dispatching sequentially one of the doses after the other into the input line.
Patent NZ-609117-A (NZ)
Title: Auto-injector
Inventor: KEMP THOMAS MARK
IPC: A61M5/20
Filed: 2011-10-06
Abstract: Disclosed is an automatic injector or syringe plunger operator with multiple safety interlocks to allow safe operation by a non-skilled user or operator. The auto-injector (1) for administering a medicament (M) comprises a tubular chassis (2) and a carrier subassembly, comprising a tubular carrier (7) slidably arranged in the chassis (2). The carrier (7) contains a syringe (3), a drive spring (8) and a plunger (9) for forwarding load of the drive spring (8) to a stopper (6) arranged in the syringe (3). The syringe (3) is locked for joint axial translation with the carrier (7). A control spring (19) is connectable to the carrier (7) by first interlock means (20) for needle insertion, wherein the whole carrier subassembly is advanced. Second interlock means (11, 13, 15) are arranged for releasing the drive spring (8) when the carrier (7) has at least almost reached an injection depth thus delivering the medicament (M). The first interlock means (20) are arranged for decoupling the control spring (8) from the carrier (7) and coupling it to the chassis (2) for advancing it over the needle (4) into a needle safe position.
Patent NZ-625051-A (NZ)
Title: Combination therapy with interferon and andrographolides for multiple sclerosis
Inventor: HANCKE OROZCO JUAN L
IPC: A61K38/21
Filed: 2012-12-19
Abstract: Disclosed is the combination therapy of interferon and a composition of Formula 1, such as andrographolide, for the treatment of demyelinating diseases and fatigue.
Patent NZ-626764-A (NZ)
Title: Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof
Inventor: BRUHEIM INGE
IPC: A23L5/40
Filed: 2012-12-21
Abstract: The present disclosure contemplates the creation of a low fluoride crustacean oil processed from a phospholipid-protein complex (PPC) formed immediately upon a crustacean (i.e., for example, krill) catch. Further, the crustacean oil may also have reduced trimethyl amine and/or trimethyl amino oxide content. The process comprises disintegrating the crustaceans into smaller particles, adding water, heating the result, adding enzyme(s) to hydrolyze the disintegrated material, deactivating the enzyme(s), removing solids from the enzymatically processed material to reduce fluoride content of the material, separating and drying the PPC material. Then, using extraction with supercritical C02 or supercritical dimethyl ether, and/or ethanol as solvents, krill oil, inter alia, is separated from the PPC. In the extraction the krill oil can be separated almost wholly from the feed material. Particularly disclosed is a crustacean oil composition, comprising phospholipids and where said phospholipids comprise phosphatidylethanolamine in the range of 1.4 to 4.9 w/w,resulting in a clear red colour due to a minimal oxidation, and/or degradation and formation of dark/brown colour, wherein said phospholipids are between 39-52 wt%, wherein said phospholipids comprise at least 2 wt % phospatidylethanolamine, 65 wt% phosphatidylcholine and maximum 2.4 wt% lysophasphatidylcholine.
Patent NZ-701262-A (NZ)
Title: Anti-viral properties of aloe vera and acquired immune deficiency syndrome (aids) treatment
Inventor: DANHOF IVAN E
IPC: A61P31/18
Filed: 2011-07-20
Abstract: Disclosed is a formulation for use in the treatment, amelioration of symptoms or both of Acquired Immune Deficiency Syndrome (AIDS) or a HIV infection in a subject comprising a first and a second component, wherein the first component comprises: a sterile injectable polymannan extract formulation comprising one or more aloe polysaccharides, wherein the aloe polysaccharides comprise one or more small chain, medium chain, large chain, very large chain polysaccharides, or any combinations thereof with a molecular weight ranging from 2,000,000-10,000,000 Daltons; and the second component comprises an oral formulation comprising: one or more aloe anthraquinones, diacetyl anthraquinone, and combinations thereof; and a freeze dried aloe powder, an aloe juice, an aloe gel or a combination wherein the powder is administered as is or after reconstitution in a liquid.
Patent NZ-705244-A (NZ)
Title: A lens design and method for preventing or slowing the progression of myopia
Inventor: YE MING
IPC: G02C7/06
Filed: 2009-07-31
Abstract: A lens 1 for preventing myopia or reducing the progression of myopia, the lens comprising an optical portion 10 extending outwardly from a lens center to an outer periphery of the optical portion 10, the optical portion 10 having a central vision region 40 and a peripheral region, and a carrier portion 20 connected to the outer periphery of the optical portion 10 by a blending zone 30 of the carrier portion 20, the carrier portion 20 extending outwardly from the outer periphery of the optical portion 10 to an outer periphery of the carrier portion 20. The lens has a power profile that creates on-axis and off-axis myopic defocus to reduce or remove on-axis and off-axis defocus created by optics in the eye of a person wearing the lens, the profile creating the on-axis and off-axis defocus by providing an increase in positive (Plus) power for light rays passing through the central vision and peripheral regions of the optical portion. The power profile has a first increase in positive (plus) power that ranges from a minimum first positive (plus) power of about 0.5 diopters to a maximum first positive (plus) power of about 1.5 diopters over a radial distance from the lens center ranging from a first radial distance of about 1.5 mm to a second radial distance of about 3.0 mm. The power profile has a second minimum increase in positive (plus) power that is equal to the first maximum positive (plus) power at the second radial distance, and a second maximum increase in positive (plus) power that is at least 0.5 diopters greater than the first maximum positive (plus) power at a third radial distance, where the third radial distance is at least 0.5 mm greater than the second radial distance.
Patent NZ-705466-A (NZ)
Title: Methods for joint calling of biological sequences
Inventor: LEONARD ERIC TRIGG
IPC: G06F19/22
Filed: 2013-08-21
Abstract: A method of calling a target biological sequence of a biological sequence source based on a set of sequence reads is disclosed. The method is performed by one or more processors executing program instructions stored on one or more memories. The instructions causing the one or more processors to perform the method comprising: obtaining biological sequence read information from a target biological sequence source and a second biological sequence source, modeling probabilities of occurrence of possible values of a set of random variables using a Bayesian network, providing one or more likely values for one or more random variables in the set of random variables and generating likely values for the target biological sequence using the Baysean network. The target source and the second source are genetically related and the set of random variables comprises a set of sequence reads that correspond to the target biological sequence source; a biological sequence of the target biological sequence source; a set of sequence reads that correspond to the second biological sequence source; and a biological sequence of the second biological sequence source and one or more random variables chosen from: contamination of a set of sequence reads that correspond to a biological sequence source; the copy number of a genomic sequence of a biological sequence source; the presence of de novo mutation in a genomic sequence of a biological sequence source; and a phenotypic trait.
Patent NZ-729726-A (NZ)
Title: Combined hot water and air heating and conditioning system including heat pump
Inventor: DEIVASIGAMANI SRIDHAR
IPC: F24H6/00
Filed: 2015-08-20
Abstract: A combined hot water and air heating and conditioning system including a first heat exchanger, a heat pump, a chilling tower loop, a burner and a second heat exchanger to provide hot water, air heating and air cooling. The system provides hot water, air heating and cooling all in one single unit. The system utilizes a heat pump to remove heat from ambient air and transfer the rejected heat into a hot water system, thereby using waste heat to heat the hot water system. The system utilizes a heat exchanger not only for the purpose of transferring heat from a heating source to a fluid in the heat exchanger but also for the purpose of dissipating heat from the fluid in the heat exchanger to the surroundings of the heat exchanger, thereby allowing a heat pump to act both as an air heating and conditioning device.
Patent NZ-734946-A (NZ)
Title: Combination treatment protocol
Inventor: EASTMAN ALAN R
IPC: A61K31/343
Filed: 2016-03-02
Abstract: The present disclosure provides a combination of a compound of formula (I) or its disodium phosphate ester prodrug with ibrutinib and a specific mode of administration and a method for treating chronic lymphocytic leukemia (CLL).
Patent NZ-735940-A (NZ)
Title: Greeting card with squeeze trigger activation
Inventor: KATALINA SPECK
IPC: B42D15/04
Filed: 2017-09-29
Abstract: The present disclosure and related inventions describe a greeting card with audio capabilities and party blower. The greeting card can include a squeeze trigger which initiates audio playback and the unfurling of the party blower. Release of the squeeze trigger causes the retraction of the party blower.
Patent NZ-746688-A (NZ)
Title: Oro-nasal patient interface
Inventor: BARLOW ADAM
IPC: A61M16/08
Filed: 2014-05-14
Abstract: Disclosed is a CPAP facial mask for assisting with sleep apnoea or other breathing obstruction conditions. The patient interface system provides breathable gas to a patient, with a cushion assembly of a nasal cushion to define a nasal gas chamber; an oral cushion to define an oral gas chamber distinct from said nasal gas chamber; and a decoupling structure disposed between the nasal cushion and the oral cushion. A positioning and stabilizing structure has a pair of lower side straps; and a pair of lower clips configured to releasably attach a corresponding one of the pair of lower side straps of the positioning and stabilizing structure to the cushion assembly. Each of the pair of lower attachment features is made from a thermoplastic elastomer and each of the pair of lower attachment features has a first magnet embedded inside. A faceplate is fixed to the oral cushion; and a frame releasably attachable to the faceplate, where the pair of lower attachment features are fixed to the frame. The frame is more rigid than the lower attachment features. The pair of lower attachment features are molded onto the frame.
Patent NZ-747821-A (NZ)
Title: Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
Inventor: CHESWORTH RICHARD
IPC: C07D405/12
Filed: 2013-12-20
Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described.
Patent NZ-750642-A (NZ)
Title: Compounds and methods for reducing tau expression
Inventor: KORDASIEWICZ HOLLY
IPC: C12N15/113
Filed: 2017-09-29
Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Tau mRNA in a cell or animal, and in certain instances reducing the amount of Tau protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include loss of memory, loss of motor function, and increase in the number and/or volume of neurofibrillary inclusions. Such neurodegenerative diseases include tauopathies, Alzheimer’s Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, and Dravet’s Syndrome. In particular a compound is provided comprising a gapmer with the nucleobase sequence CCGTTTTCTTACCACCCT and wherein the internucleoside linkages are, from 5’ to 3’, sossssssssssssoss, wherein each s is a phosphorothioate linkage and each o is a phosphodiester linkage.
Patent PT-103915-A (PT)
Title: Pavimentos cerâmicos fotoluminescentes para áreas de risco e emergência de portadores de deficiência e processo para a sua obtenção.
Inventor: FERNANDES MARIA HELENA FIGUEIRA VAZ
IPC: F21K2/06
Filed: 2007-12-28
Abstract: A PRESENTE INVENÇÃO DIZ RESPEITO A PAVIMENTOS CERÂMICOS, FOTOLUMINESCENTES, QUE COMPREENDEM UMA FOTOLUMINESCENTE (1), (3), (5) E (7) E PRODUZEM O CONTRASTE COM AS RESPECTIVAS SUPERFÍCIES (2), (4), (6) E (8) DOS SUBSTRATOS NÃO-LUMINESCENTES (INERTE). TAIS PISOS SÃO OBTIDOS EM PLACAS CERÂMICAS, POR PRENSAGEM EM MOLDE, COM CAMADA FOTOLUMINESCENTE, COZIDOS EM FORNOS, E PODEM SER COMBINADOS A COMPOR UM EXCLUSIVO SISTEMA DE PAGINAÇÃO FOTOLUMINESCENTE MULTISENSORIAL (RELEVOS) PARA PESSOAS PORTADORAS DE DEFICIÊNCIAS UTILIZAREM, NO ESCURO, EM SITUAÇÕES DE EMERGÊNCIA, E QUE POSSIBILITAM RÁPIDA EVACUAÇÃO MEDIANTE O USO DE AUXÍLIOS DE MOBILIDADE (EX. BENGALA, CADEIRA DE RODAS, ANDADORES).
Patent PT-106371-A (PT)
Title: Formulações utilizando, o extrato obtido do caldo fermentado de um ou mais tipos de frutas, contendo diversos compostos bioactivosvos naturais, complementados ou não com outros extratos vegetais - em produtos medicinais, veterinários e cométicos
Inventor: ALBUQUERQUE MARCOS ANTONIO
IPC: A61K36/00
Filed: 2012-06-08
Abstract: TRATA A PRESENTE INVENÇÃO DE FORMULAÇÕES UTILIZANDO O EXTRATO OBTIDO DO CALDO FERMENTADO DE UM OU MAIS TIPOS DE FRUTAS, CONTENDO DIVERSOS COMPOSTOS BIOACTIVOS NATURAIS, COMPLEMENTADOS OU NÃO COM OUTROS EXTRATOS VEGETAIS, EM PRODUTOS, MEDICINAIS, VETERINÁRIOS E COMÉTICOS, DE USO TÓPICO, INDICADAS PARA: - RECUPERAÇÃO DE LESÕES PROVOCADAS POR DERMOABRASÃO; - DOENÇAS GENÉTICAS (ICTIOSE), CONGÊNITAS (DERMATITE ATÓPICA, QUERATINIZAÇÃO, PELE SECA) OU PSICOSSOMÁTICA (PSORIASE); - PROCESSOS INFLAMATÓRIOS SUPERFICIAIS (ACNES,ABCESSOS) - QUEIMADURAS E FERIDAS PROFUNDAS, HEMORROIDAS, FISURA ANAL; - UTILIZAÇÃO EM FSIOTERAPIA E TRAUMATOLOGIA; - UTILIZAÇÃO EM VETERINÁRIA, NA CICATRIZAÇÃO DE LESÕES CUTÂNEAS E CIRÚRGICAS, TRAUMATISMO, INSETICIDA, BACTERICIDA E REPELENTE; - UTILIZAÇÃO EM COSMÉTICO PARA HIGIENE (DESODORANTES, SABONETES SÓLIDOS E LIQUÍDOS, SHAMPOOS, CONDICIONADORES E CREME DENTAL PARA TRATAMENTO DE GENGIVITE E HIDRATAÇÃO DO CORPO, TRATAMENTO DE RUGAS, ESTRIAS, MAQUILAGEM PERMANENTE.